Drug Toxicity
Conditions
Brief summary
Cisplatin is one of the first-line drugs used against many malignancies, such as lung cancer, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, urothelial cancer, bladder cancer and testicular cancer. The usage of Cisplatin is limited by its severe nephrotoxicity, which particularly affects the proximal tubule epithelial cells (PTEC).Several studies suggest role of NAC in ameliorating Cisplatin induced nephrotoxicity, although definitive data is lacking. N-Acetylcysteine (NAC) is a thiol-containing antioxidant, which not only acts as a precursor of glutathione but also as a direct antioxidant .There are multiple postulated mechanisms for NAC's nephroprotection. NAC is a low-cost, easily available drug with a very good safety profile and therefore can be added as a support medication during treatment with cisplatin. The investigators plan to administer 1200 mg oral NAC 12 hours before chemotherapy and then daily at night for the subsequent 6 days, with an objective to ascertain its nephroprotective role in population receiving Cisplatin/-based chemotherapy.
Interventions
DRUGN-Acetylcysteine
Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
DRUGChemotherapy
Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
Sponsors
Foundation University Islamabad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
It will be a two-arm study with 35 patients in each arm. After taking informed consent, a total of 70 patients will be enrolled. The patients will be enrolled by convenience nonprobability sampling technique. Then they will be randomized to the N-Acetylcysteine plus chemotherapy and chemotherapy-alone arms.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adult female outpatients with non-hematological malignancies (Breast, ovary and head and neck squamous cell carcinomas) * Having Eastern Cooperative Oncology Group(ECOG) Performance Status ≤2 who had never received platinum based Chemotherapy in past and were now scheduled to receive high-dose cisplatin chemotherapy. * Patients were required to have estimated glomerular filtration rate (GFR)(according to Cockcroft-Gault formula) ≥ 60 ml/min at start of chemotherapy regimen with normal Blood Counts, Liver, and kidney function tests
Exclusion criteria
* Patients who had poor performance status i.e., ECOG Performance Status 3 or 4 * Who declined to participate at any time during the course of the study * Patients having hepatic failure (Liver Function tests \>3 times of upper limit normal) * Patients who did not tolerate the use of NAC or were administered the drug \<70% of the time * Patient who were receiving concurrent nephrotoxic drugs, or having history of Hypersensitivity to N-Acetyl cysteine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of Acute kidney injury to participant | 18 weeks | Acute kidney injury will be assessed by RIFLE criteria that will be calculated for patients |
| Blood urea nitrogen of participant | 18 weeks | Blood samples collected and measured in laboratory with the unit mg/dl |
| Serum creatinine of participant | 18 weeks | Blood samples collected and measured in laboratory with the unit mg/dL |
| Creatinine clearance of participant | 18 weeks | It will be calculated using Cockroft-Gault formula , unit ml/min |
Countries
Pakistan
Outcome results
None listed